Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lab-Grown lung tumors help scientists test new cancer drugs

NCT ID NCT07610616

Knowledge-focused Sponsor: Guangzhou Institute of Respiratory Disease Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing antibody-drug conjugates (ADCs) on tiny lab-grown versions of lung cancer tumors called organoids. The goal is to understand how these drugs kill cancer cells and interact with the immune system. Researchers will study 10 people with HER2- or TROP2-positive non-small cell lung cancer to find the best drug combinations.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
antibody-drug conjugates (ADCs) combined with tyrosine kinase inhibitors or immune checkpoint blockers
What this could lead to
If successful, this could help doctors choose the most effective ADC drug combinations for patients with HER2- or TROP2-positive lung cancer.
What could go wrong
This is a very small, early-stage lab study with only 10 participants. Results may not translate to real-world patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with a pathological diagnosis of non-small cell lung cancer (NSCLC), whose tumor patient-derived organoids (PDOs) exhibited strong or weak positive expression of the HER2 or TROP2 targets as determined by immunohistochemistry.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years. * Availability of patient-derived organoids (PDOs) with matched autologous tumor-infiltrating lymphocytes (TILs) or peripheral blood mononuclear cells (PBMCs) from non-small cell lung cancer (NSCLC) cases. * Patients currently undergoing or scheduled to receive Trastuzumab deruxtecan (T-DXd) therapy who meet clinical eligibility criteria. * Provision of written informed consent. * PDOs exhibiting strong positive HER2 and TROP2 expression by immunohistochemistry (IHC) assigned to the experimental group. * PDOs exhibiting weak positive HER2 and TROP2 expression by IHC assigned to the negative control group. Exclusion Criteria: * PDOs derived from patients with pathologically confirmed small cell lung cancer (SCLC). * Unavailability of matched autologous PDOs, TILs, or PBMCs. * Presence of any contraindications to T-DXd treatment. * Presence of other serious comorbidities resulting in an estimated survival of \<3 months. * Pregnant or breastfeeding women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2 positive or TROP2 positive non-small cell lung cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2 positive or TROP2 positive non-small cell lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of Guangzhou Medical University

    RECRUITING

    Guangzhou, Guangdong, China